PE Tech Report


Like this article?

Sign up to our free newsletter

Tridek-One closes a €16m financing round led by Pureos Bioventures

Tridek-One SAS, a biotech start-up specialised in the research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16.1m) financing round led by the Swiss VC Pureos Bioventures.

New investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), as well as historical investors AdBio partners and Advent Life Sciences also participated in the round. 

The funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organisation. The company previously raised €3 million ($3.02 million) in a first round in 2019 involving AdBio partners (FR) and Advent Life Sciences (UK).
Founded in 2018 by Dr Giuseppina Caligiuri and Pr Antonino Nicoletti, researchers at INSERM Unit 1148 (Paris, France), with the support of historical investor AdBio partners, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.
Tridek-One has also appointed Laurence de Schoulepnikoff, a seasoned pharma and biotech professional with broad experience in transactions and R&D operations, as chief executive officer as of 1 July, 2022. She has worked in VC-funded biotech start-ups and mid-size private companies as well as large corporate organisations. Laurence joins Tridek-One from AMAL Therapeutics, a Swiss biotechnology company focused on therapeutic cancer vaccines, where she spent the last three years as chief business officer and chief operating officer. 

Following the fundraising, Klaus Breiner of Pureos Bioventures, and Benoit Barteau of Bpifrance, are joining the company’s board of directors. Erik van den Berg, CEO of AM-Pharma, joins as independent chairman of the board of directors.

Like this article? Sign up to our free newsletter